Physician profile
James Long
NPI 1487650552
$1,606.15
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $170 · 2021: $884.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $437.16 | 2019-2021 | |
| Boston Scientific Corporation | $191.50 | 2019-2021 | |
| Novo Nordisk INC | $165.36 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.51 | 2019-2021 | |
| Amgen INC. | $113.05 | 2021 | |
| Esperion Therapeutics, INC. | $111.49 | 2021 | |
| Amarin Pharma, INC. | $96.91 | 2019 | |
| Eisai INC. | $63.34 | 2019 | |
| Pfizer INC. | $41.25 | 2021 | |
| Lilly USA, LLC | $39.11 | 2019-2021 | |
| Nalpropion Pharmaceuticals LLC | $37.47 | 2019 | |
| Currax Pharmaceuticals LLC | $32.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $31.62 | 2021 | |
| Merck Sharp & Dohme LLC | $17.93 | 2021 | |
| Vivus LLC | $16.13 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $15.02 | 2021 | |
| Sanofi Pasteur INC. | $14.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.82 | 2021 | |
| Althera Pharmaceuticals LLC | $12.31 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.